BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
October 18 2023 - 9:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, is pleased to announce that BriaCell will be presenting at
the following two upcoming scientific conferences.
The 2023 SITC 38th Annual Meeting will
be taking place November 3-5, 2023 at San Diego Convention
Center, San Diego, CA.
Abstract Title: Development and
Mechanism of Action of a Novel Cellular Immunotherapeutic Platform
for the Treatment of CancerAbstract Number:
419Session Date and Time: Friday November 3, 2023
9:00 AM - 6:00 PM
The 2023 San Antonio Breast Cancer Symposium®
will be taking place December 5-9, 2023 at Henry B. Gonzalez
Convention Center, San Antonio, TX.
Poster 1:Abstract
Title: CD8+ Tumor Infiltrating Lymphocytes Turn a
Cold Tumor Hot in Metastatic Breast CancerSubmission
ID: 1577766Presentation
ID: PO1-20-12Spotlight
Session: Poster Session 1Session Date and
Time: Wednesday December 6, 2023 12:00 PM - 2:00
PM
Poster 2: Abstract
Title: Analysis of Antibody Response to SV-BR-1-GM
Therapeutic Vaccine in Breast Cancer Patients Using Human Protein
Microarrays: Potential Correlations with Therapy
ResponseSubmission
ID: 1578637Presentation
ID: PO2-13-06Spotlight
Session: Poster Session 2Session Date and
Time: Wednesday December 6, 2023 5:00 PM - 7:00
PM
Poster 3: Abstract
Title: Randomized Phase 2 of Bria-IMT™, an Allogenic Human
Cell Line with Antigen Presenting Activity, in Heavily Pretreated
Metastatic Breast CancerSubmission ID:
1580375Presentation ID: PO3-05-12Spotlight
Session: Poster Session 3Session Date and
Time: Thursday December 7, 2023 12:00 PM - 2:00 PM
Following the presentation, copies of the
posters will be posted on
https://briacell.com/scientific-publications/.
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including those about presenting at two upcoming
scientific conferences, are based on BriaCell’s current
expectations and are subject to inherent uncertainties, risks, and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully under the heading “Risks and
Uncertainties” in the Company's most recent Management’s Discussion
and Analysis, under the heading "Risk Factors" in the Company's
most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Sep 2023 to Sep 2024